Detailed overview on rare malignant ovarian tumors.
Adenocarcinoma, Clear Cell
/ pathology
Adenocarcinoma, Mucinous
/ pathology
Brenner Tumor
/ pathology
Carcinoma, Small Cell
/ pathology
Carcinosarcoma
/ pathology
Cystadenocarcinoma, Serous
/ pathology
Female
Humans
Neoplasms, Germ Cell and Embryonal
/ pathology
Ovarian Neoplasms
/ pathology
Rare Diseases
/ pathology
Sex Cord-Gonadal Stromal Tumors
/ pathology
Clear cell carcinoma
Germ cell tumors
Mucinous carcinoma
Sex cords stromal tumors
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
26
11
2019
revised:
29
12
2019
accepted:
13
01
2020
pubmed:
3
3
2020
medline:
27
3
2020
entrez:
3
3
2020
Statut:
ppublish
Résumé
The group of rare malignant ovarian tumors includes the group of germ cell tumors, sex cords stromal ovarian tumors, small cell carcinoma, malignant Brenner tumors, rare epithelial tumors such as mucinous carcinoma, clear cell carcinoma, or low-grade serous carcinoma, as well as ovarian carcinosarcoma. Together they comprise about 10% of all ovarian tumors. Due to their low prevalence and their heterogeneity, data and treatment recommendations are limited. Even though all ovarian tumors are staged according to the FIGO staging of epithelial ovarian tumors, treatment differs especially in germ cell tumors and sex cords stromal ovarian tumors. Non-epithelial ovarian tumors can arise from a variety of ovarian precursor cells such as germ cells, granulosa cells, theca cells, or stromal fibroblasts. As can be expected already due to their divergent precursor lesions, these malignancies are substantially different but united by their rarity. This overview article gives a comprehensive summary on the pathology and clinical presentation, as well as therapy recommendations of a selection of those rare ovarian tumors, based on the latest national guidelines and related important publications.
Identifiants
pubmed: 32115180
pii: S0007-4551(20)30080-1
doi: 10.1016/j.bulcan.2020.01.011
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
385-390Informations de copyright
Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.